Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Elena Ambrogini

CredentialsInternal Medicine
Endocrinology and Metabolism
TitleAssociate Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
DivisionInternal Med Endo
AddressS310B Shorey
4104 Outpatient Circle
Mail Slot # 587
Little Rock AR 72205
Phone501-686-5130
ORCID ORCID Iconeambrogini@uams.edu Additional info
vCardDownload vCard
    Other Roles
    Associate Professor of Medicine Staff Endocrinologist at CAVHS

    Collapse Overview 
    Collapse overview
    Dr. Elena Ambrogini received her medical degree from the University of Pisa in Italy. She continued her training and received a Ph.D. in Endocrine and Metabolic Sciences from the same university. In addition, Dr. Ambrogini completed several internships, residencies, and fellowships, focusing on endocrinology, metabolic diseases, and internal medicine. She is currently an Associate Professor of Medicine in the Division of Endocrinology and Metabolism. Dr. Ambrogini is a member of the American Society for Bone and Mineral Research and the Endocrine Society. She has received the Thomas E. Andreoli Award for excellence in internal medicine as well as the ASBMR Felix Bronner Young Investigator Award for the top ranked abstract by a young investigator at the American Society for Bone and Mineral Research. Dr. Ambrogini focuses much of her time on research. The main research interests of Dr. Ambrogini are in the field of endocrinology and particularly in bone and calcium homeostasis, and thyroid diseases. Her work is particularly focused on the pathophysiology of osteoporosis and metabolic bone diseases. These studies have been the object of oral presentations at International Meetings and publications.


    Collapse Affiliation 
    Collapse Translational Research Institute: Clinical and Translational Science Award
    UAMS Tobacco Funds and Translational Research Institute
    239 G1-50893-01
    PI
    Atherosclerosis, osteoporosis, and innate immunity: a research career development plan
    $150,000
    01/2015–06/2018
    2.4 calendar months


    UAMS Tobacco Funds and Translational Research Institute
    239-G1-53545-01
    PI
    Antibodies against oxidation specific epitopes affect glucose metabolism
    $9,761
    07/2018-06/2019
    0.5 calendar months


    Barton Endowment individual pilot study
    271 G1-51451-99
    PI
    Antibodies against oxidation-specific epitopes have an anabolic effect in murine bone
    $25,000
    05/2016–12/2017
    0.5 calendar months

    Collapse member of
    asbmr
    endocrine society
    Collapse collaborator
    Dr, Joseph L Witztum
    Collapse clinical activities
    uams outpatient clinic
    uams inpatient endocrine service
    CAVHS outpatient endocrine clinic
    CAVHS thyroid clinic
    CAVHS inpatient endocrine service

    Collapse Biography 
    Collapse Leadership and Administrative Roles
    I. University of Arkansas for Medical Sciences

    • Chair, Fellowship in Endocrinology and Metabolism Program Evaluation Committee (2016-present)

    • Member of the Fellowship in Endocrinology and Metabolism Program Clinical Competency Committee (2020-present)

    • Coordinator of the ENT- Radiology- Endocrine surgery-Endocrinology multidisciplinary joined conference

    • Interviewer for Medical student applicants (2019-present)

    • Interviewer for Internal Medicine residency program applicants (2015-present)

    • Reviewer of applications and Interviewer for Endocrinology and Metabolism Fellowship Program applicants (2015-present)

    • Poster judge at the Annual Medicine Research Symposium (2019-present)

    • Creator and manager of the annual inpatient/call schedule for Clinical Faculty for the Division of Endocrinology (2015-present)

    • Member of the Inclusion and Diversity Commitee (2021-present)


    II. Central Arkansas Veterans Healthcare System

    • Co-manager of the Thyroid ultrasound and biopsy program (2015-present)

    • Creator and manager of the annual inpatient/call schedule for Clinical Faculty for the Division of Endocrinology (2015-present)

    • Member of the IRB Committee (2020-present)




    III. National
    American Society for Bone and Mineral Research

    • Annual meeting oral presentations moderator (2019-present)
    • Member of the Annual meeting abstract reviewer committee (2020-present)

    Collapse education and training
    University of Pisa, Pisa, ItalyMS07/2000Medicine
    Department of Endocrinology and Metabolism University of Pisa, Pisa, Italy11/2006Residency in Endocrinology and Metabolism
    Univeristy of Pisa, Pisa, ItalyPhD12/2009Endocrine and Metabolic Sciences
    University Arkansas for Medical Sciences, Little Rock, AR06/2013Residency in Internal Medicine
    University Arkansas for Medical Sciences, Little Rock, AR12/2014Fellowship in Endocrinology and Metabolism
    Collapse awards and honors
    2021Service and Professionalism , UAMS
    2020Special Contribution Award for the significant contribution during the COVID pandemic , CAHVS
    2019Physician of the year award , CAVHS
    2019 Research Team Travel Grant Award, ASBMR
    2018Young Investigator Travel Grant Award, ASBMR
    2016Young Investigator Travel Grant Award , ASBMR
    2013The Thomas E. Andreoli Award for excellence in internal medicine , UAMS
    2010 ASBMR Felix Bronner Young Investigator Award for the top ranked abstract presented , UAMS
    2010Best Graduation thesis, Univeristy of Pisa

    Collapse Teaching 
    Collapse teaching overview
    Dr. Ambrogini is fully committed to all aspects of academic medicine. In addition to research and clinical care, she is committed to teaching. As such, she is actively involved in educating fellows, residents, medical students and physician assistant students.
    Dr. Ambrogini is a teaching clinical attending for the endocrinology fellows in both the outpatient and the inpatient services at the University of Arkansas for Medical Sciences (UAMS) and the Central Arkansas Veterans Healthcare System (CAVHS). She provides core curriculum lectures for fellows (3 lectures/year) and mentors fellows during their clinical research activity. Dr. Ambrogini is the Chair of the Program Evaluation Committee for the fellowship in Endocrinology and Metabolism since 2016 and also a member of the Clinical Competence Committee for the fellowship program since 2020.
    Dr. Ambrogini is the supervisor attending for internal medicine and radiology residents during their endocrinology inpatient rotation and supervised internal medicine residents as attending in the inpatient internal medicine ward service in 2015. She also supervises two internal medicine residents every academic year in her general endocrine clinic at UAMS as part of their outpatient curriculum. Dr. Ambrogini presents endocrine topics to the internal medicine residents during their yearly lecture series. She also interviews applicants for the residency in Internal Medicine and also serves as a Poster judge at the Annual Internal Medicine Research Symposium.
    Dr. Ambrogini serves as clinical preceptor in the Practice of Medicine for first year medical student since 2019 and teaches medical student diabetes type 1 and 2 with a standard lecture and team base learning since 2020. Those lectures are part of the Endocrine/Reproduction Model. She is a mentor for first year medical students for his summer research as part of the Honors in Research Program. Dr. Ambrogini interviews applicants for medical school at UAMS.
    Since 2014, Dr. Ambrogini serves as clinical preceptor for Physician Assistant Student at UAMS (1-2 students/semester). This activity includes reviewing the clinical history, the physical exam, the diagnostic assessment and the therapeutic plan with Dr. Ambrogini who guides them through the process.
    Dr. Ambrogini has presented 9 between Grand rounds and Med-Path presentations at both UAMS and CAVHS
    All the evaluation from fellows, internal medicine residents, medical students and physician assistant students have been overwhelmingly positive and she has been rated as excellent in all categories.


    Collapse Research 
    Collapse research overview
    Dr. Ambrogini is a physician scientist with extensive training in clinical and basic science, and a special interest in the pathophysiology of bone diseases. During the first part of her training as a resident in Endocrinology and Metabolism at the University of Pisa, Italy, she performed clinical and translational research on primary hyperparathyroidism. She conducted one of the first randomized controlled clinical trials on asymptomatic primary hyperparathyroidism, demonstrating the benefits of the surgical approach on bone mass and quality of life. The results of these studies were published in one of the leading journals in Endocrinology, the “Journal of Endocrinology and Clinical Metabolism”. She was also involved in translational research investigating the relationship between somatic and germline mutations with clinical manifestation of primary hyperparathyroidism (sporadic and familiar) and parathyroid carcinoma. After completion of her first residency in Endocrinology and Metabolism, she entered a PhD program at the University of Pisa. To perform her PhD studies and to follow her interest in bone diseases, she joined the laboratory of Dr. Stavros C. Manolagas at UAMS as a post-doctoral research fellow. During the three and a half years of her training under the direct supervision of Dr. Maria Almeida, she acquired extensive skills on basic research including generation of new mice models and she was involved in several projects. Her main project demonstrated the role of the FoxO transcription factors in bone pathology, and this work led to a paper in Cell Metabolism. She was also involved in projects aimed at understanding the molecular mechanism of the estrogen deficiency-induced bone loss and the role of oxidative stress in the age related-bone loss. After the end of the PhD/Post-doc training, she repeated a clinical residency in Internal Medicine and fellowship in Endocrinology and Metabolism at UAMS and pursued the career as a physician scientist in the Unites States. During her clinical training, she continued basic research in the lab, which resulted in several publications in high-impact journals. During the last year of her clinical fellowship, she began investigating the role of lipid peroxidation products in bone homeostasis, in collaboration with Dr. Witztum at the University of California in San Diego. Those studies showed, for the first time in vivo, the role of oxidation specific epitopes and the natural antibodies that defend against them in bone metabolism under both physiologic and pathologic conditions, paving the way for a new anabolic therapy for osteoporosis. The results of this work were published in Nature Communications and journal of Bone and Mineral Research. Dr. Ambrogini is currently continuing to work on this project and she has found that blocking oxidation specific epitopes prevents age-related bone loss, fat accumulation and worsening glucose intolerance. In addition, she started a translational study to investigate if endogenous levels of antibodies against oxidation specific epitopes correlate with bone mineral density in humans. She is also working to establishing a tissue back for bone specimens at UAMS.
    Her research has been supported by intramural and extramural funding. She received ~ $180.000 dollars in intramural funding. In 2018 she was a project leader in a COBRE grant (PI Dr. Charles O’Brien) and in 2019 she was awarded her independent funding with her first VA merit grant (RO1 equivalent).
    Dr. Ambrogini is an author in 31 publications (3231 citations), her H-index is 20 and i10-index is 27. She has published 85 abstracts and she have given 13 oral presentations and 17 poster presentations as first or last author at national and international meetings. Four of her oral presentations received awards from the American Society for Bone and Mineral Research. In recognition of her research and clinical contribution, she received an award by the CAVHS leadership in 2019.

    Collapse research activities and funding
    S10 OD026736     (MACKINTOSH, SAMUEL)Aug 1, 2019 - Jul 31, 2020
    NIH/Office of the Director
    Q Exactive HF-X Hybrid Quadrupole Orbitrap Mass Spectrometer
    Role: Co-Investigator

    I01BX003901     (AMBROGINI, ELENA)Jul 1, 2019 - Jun 30, 2023
    NIH
    Role of Natural Antibodies Against Oxidation Specific Epitopes in Bone Homeostasis
    Role: Principal Investigator

    P20GM125503     (O'BRIEN, CHARLES A)Feb 16, 2018 - Jan 31, 2023
    NIH
    Center for Musculoskeletal Disease Research (CMDR)
    Role: Co-Investigator

    239-G1-53545-01     (Elena Ambrogini)Jan 7, 2018 - Jun 30, 2019
    UAMS Tobacco Funds and Translational Research Institute
    Antibodies against oxidation specific epitopes affect glucose metabolism
    Role: Principal Investigator

    271 G1-51451-99     (Elena Ambrogini)May 1, 2016 - Dec 31, 2017
    Barton Endowment individual pilot study
    Antibodies against oxidation-specific epitopes have an anabolic effect in murine bone
    Role: Principal Investigator

    239 G1-50893-01     (Elena Ambrogini)Jan 1, 2015 - Jun 30, 2018
    UAMS Tobacco Funds and Translational Research Institute
    Atherosclerosis, osteoporosis, and innate immunity: a research career development plan
    Role: Principal Investigator

    P01AG013918     (MANOLAGAS, STAVROS C.)Aug 27, 1996 - Apr 30, 2018
    NIH
    Molecular and Cellular Mechanisms of Osteoporosis
    Role: Co-Investigator

    Collapse Outreach 

    Collapse Bibliographic 
    Collapse additional bibliographic sources
    The links below are provided by the researcher to provide access to external online bibliographies that they keep independently from the Profiles System.
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Palmieri M, Almeida M, Nookaew I, Gomez-Acevedo H, Joseph TE, Que X, Tsimikas S, Sun X, Manolagas SC, Witztum JL, Ambrogini E. Neutralization of oxidized phospholipids attenuates age-associated bone loss in mice. Aging Cell. 2021 08; 20(8):e13442. PMID: 34278710.
      View in: PubMed
    2. Toloza FJK, Theriot SE, Singh Ospina NM, Nooruddin S, Keathley B, Johnson SM, Payakachat N, Ambrogini E, Rodriguez-Gutierrez R, O'Keeffe DT, Brito JP, Montori VM, Dajani NK, Maraka S. Knowledge, Attitudes, Beliefs, and Treatment Burden Related to the Use of Levothyroxine in Hypothyroid Pregnant Women in the United States. Thyroid. 2021 04; 31(4):669-677. PMID: 33176609.
      View in: PubMed
    3. Almeida M, Kim HN, Han L, Zhou D, Thostenson J, Porter RM, Ambrogini E, Manolagas SC, Jilka RL. Increased marrow adipogenesis does not contribute to age-dependent appendicular bone loss in female mice. Aging Cell. 2020 11; 19(11):e13247. PMID: 33048436.
      View in: PubMed
    4. Palmieri M, Kim HN, Gomez-Acevedo H, Que X, Tsimikas S, Jilka RL, Manolagas SC, Witztum JL, Ambrogini E. A Neutralizing Antibody Targeting Oxidized Phospholipids Promotes Bone Anabolism in Chow-Fed Young Adult Mice. J Bone Miner Res. 2021 01; 36(1):170-185. PMID: 32990984.
      View in: PubMed
    5. Ambrogini E, Que X, Wang S, Yamaguchi F, Weinstein RS, Tsimikas S, Manolagas SC, Witztum JL, Jilka RL. Oxidation-specific epitopes restrain bone formation. Nat Commun. 2018 06 06; 9(1):2193. PMID: 29875355.
      View in: PubMed
    6. Iyer S, Han L, Ambrogini E, Yavropoulou M, Fowlkes J, Manolagas SC, Almeida M. Deletion of FoxO1, 3, and 4 in Osteoblast Progenitors Attenuates the Loss of Cancellous Bone Mass in a Mouse Model of Type 1 Diabetes. J Bone Miner Res. 2017 01; 32(1):60-69. PMID: 27491024.
      View in: PubMed
    7. Bartell SM, Kim HN, Ambrogini E, Han L, Iyer S, Serra Ucer S, Rabinovitch P, Jilka RL, Weinstein RS, Zhao H, O'Brien CA, Manolagas SC, Almeida M. FoxO proteins restrain osteoclastogenesis and bone resorption by attenuating H2O2 accumulation. Nat Commun. 2014 Apr 30; 5:3773. PMID: 24781012.
      View in: PubMed
    8. Iyer S, Ambrogini E, Bartell SM, Han L, Roberson PK, de Cabo R, Jilka RL, Weinstein RS, O'Brien CA, Manolagas SC, Almeida M. FOXOs attenuate bone formation by suppressing Wnt signaling. J Clin Invest. 2013 Aug; 123(8):3409-19. PMID: 23867625.
      View in: PubMed
    9. Almeida M, Iyer S, Martin-Millan M, Bartell SM, Han L, Ambrogini E, Onal M, Xiong J, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. Estrogen receptor-a signaling in osteoblast progenitors stimulates cortical bone accrual. J Clin Invest. 2013 Jan; 123(1):394-404. PMID: 23221342.
      View in: PubMed
    10. Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC. Glucocorticoids and tumor necrosis factor a increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem. 2011 Dec 30; 286(52):44326-35. PMID: 22030390.
      View in: PubMed
    11. Jilka RL, Almeida M, Ambrogini E, Han L, Roberson PK, Weinstein RS, Manolagas SC. Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration. Aging Cell. 2010 Oct; 9(5):851-67. PMID: 20698835.
      View in: PubMed
    12. Almeida M, Han L, Ambrogini E, Bartell SM, Manolagas SC. Oxidative stress stimulates apoptosis and activates NF-kappaB in osteoblastic cells via a PKCbeta/p66shc signaling cascade: counter regulation by estrogens or androgens. Mol Endocrinol. 2010 Oct; 24(10):2030-7. PMID: 20685851.
      View in: PubMed
    13. Almeida M, Martin-Millan M, Ambrogini E, Bradsher R, Han L, Chen XD, Roberson PK, Weinstein RS, O'Brien CA, Jilka RL, Manolagas SC. Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERalpha. J Bone Miner Res. 2010 Apr; 25(4):769-81. PMID: 19821774.
      View in: PubMed
    14. Ambrogini E, Almeida M, Martin-Millan M, Paik JH, Depinho RA, Han L, Goellner J, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab. 2010 Feb 03; 11(2):136-46. PMID: 20142101.
      View in: PubMed
    15. Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol. 2010 Feb; 24(2):323-34. PMID: 20053716.
      View in: PubMed
    16. Virdis A, Cetani F, Giannarelli C, Banti C, Ghiadoni L, Ambrogini E, Carrara D, Pinchera A, Taddei S, Bernini G, Marcocci C. The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment. J Clin Endocrinol Metab. 2010 Feb; 95(2):920-7. PMID: 20022989.
      View in: PubMed
    17. Almeida M, Ambrogini E, Han L, Manolagas SC, Jilka RL. Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton. J Biol Chem. 2009 Oct 02; 284(40):27438-48. PMID: 19657144.
      View in: PubMed
    18. Vignali E, Viccica G, Diacinti D, Cetani F, Cianferotti L, Ambrogini E, Banti C, Del Fiacco R, Bilezikian JP, Pinchera A, Marcocci C. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2009 Jul; 94(7):2306-12. PMID: 19401378.
      View in: PubMed
    19. Cetani F, Lemmi M, Cervia D, Borsari S, Cianferotti L, Pardi E, Ambrogini E, Banti C, Brown EM, Bagnoli P, Pinchera A, Marcocci C. Identification and functional characterization of loss-of-function mutations of the calcium-sensing receptor in four Italian kindreds with familial hypocalciuric hypercalcemia. Eur J Endocrinol. 2009 Mar; 160(3):481-9. PMID: 19073830.
      View in: PubMed
    20. Cetani F, Pardi E, Ambrogini E, Banti C, Viacava P, Borsari S, Bilezikian JP, Pinchera A, Marcocci C. Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment. J Endocrinol Invest. 2008 Oct; 31(10):900-4. PMID: 19092296.
      View in: PubMed
    21. Cetani F, Pardi E, Banti C, Borsari S, Ambrogini E, Vignali E, Cianferotti L, Viccica G, Pinchera A, Marcocci C. HRPT2 gene analysis and the diagnosis of parathyroid carcinoma. Expert Rev Endocrinol Metab. 2008 May; 3(3):377-389. PMID: 30754207.
      View in: PubMed
    22. Cetani F, Pardi E, Ambrogini E, Viacava P, Borsari S, Lemmi M, Cianferotti L, Miccoli P, Pinchera A, Arnold A, Marcocci C. Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation. Endocr Relat Cancer. 2007 Jun; 14(2):493-9. PMID: 17639062.
      View in: PubMed
    23. Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G, Oppo A, Miccoli P, Berti P, Bilezikian JP, Pinchera A, Marcocci C. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab. 2007 Aug; 92(8):3114-21. PMID: 17535997.
      View in: PubMed
    24. Cetani F, Ambrogini E, Viacava P, Pardi E, Fanelli G, Naccarato AG, Borsari S, Lemmi M, Berti P, Miccoli P, Pinchera A, Marcocci C. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol. 2007 May; 156(5):547-54. PMID: 17468190.
      View in: PubMed
    25. Cetani F, Pardi E, Ambrogini E, Lemmi M, Borsari S, Cianferotti L, Vignali E, Viacava P, Berti P, Mariotti S, Pinchera A, Marcocci C. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin Endocrinol (Oxf). 2006 Feb; 64(2):146-52. PMID: 16430712.
      View in: PubMed
    26. Marinò M, Morabito E, Altea MA, Ambrogini E, Oliveri F, Brunetto MR, Pollina LE, Campani D, Vitti P, Bartalena L, Pincheral A, Marcocci C. Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. J Endocrinol Invest. 2005 Mar; 28(3):280-4. PMID: 15952415.
      View in: PubMed
    27. Ambrogini E, Toraldo G, Marcocci C. Post-menopausal osteoporosis: is it an autoimmune disease? J Endocrinol Invest. 2005; 28(10 Suppl):43-7. PMID: 16550722.
      View in: PubMed
    28. Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, Cianferotti L, Ambrogini E, Gazzerro E, Colussi G, Berti P, Miccoli P, Pinchera A, Marcocci C. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab. 2004 Nov; 89(11):5583-91. PMID: 15531515.
      View in: PubMed
    29. Cetani F, Ambrogini E, Faviana P, Vitti P, Berti P, Pinchera A, Marcocci C. Spontaneous short-term remission of primary hyperparathyroidism from infarction of a parathyroid adenoma. J Endocrinol Invest. 2004 Jul-Aug; 27(7):687-90. PMID: 15505996.
      View in: PubMed
    30. Tonacchera M, Agretti P, de Marco G, Elisei R, Perri A, Ambrogini E, De Servi M, Ceccarelli C, Viacava P, Refetoff S, Panunzi C, Bitti ML, Vitti P, Chiovato L, Pinchera A. Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein. Clin Endocrinol (Oxf). 2003 Oct; 59(4):500-6. PMID: 14510914.
      View in: PubMed
    31. Cetani F, Pardi E, Vignali E, Borsari S, Picone A, Cianferotti L, Ambrogini E, Miccoli P, Pinchera A, Marcocci C. MEN1 gene alterations do not correlate with the phenotype of sporadic primary hyperparathyroidism. J Endocrinol Invest. 2002 Jun; 25(6):508-12. PMID: 12109621.
      View in: PubMed
    32. Vignali E, Picone A, Materazzi G, Steffe S, Berti P, Cianferotti L, Cetani F, Ambrogini E, Miccoli P, Pinchera A, Marcocci C. A quick intraoperative parathyroid hormone assay in the surgical management of patients with primary hyperparathyroidism: a study of 206 consecutive cases. Eur J Endocrinol. 2002 Jun; 146(6):783-8. PMID: 12039698.
      View in: PubMed
    Ambrogini's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description